CYTK vs RCUS

For growth investors, Cytokinetics, Incorporated (CYTK) is the stronger pick with 376.

6% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Analysts rate Cytokinetics, Incorporated (CYTK) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cytokinetics, Incorporated (CYTK) delivered a total return of +206.

6%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: CYTK returned +849. 5% versus RCUS's +49. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cytokinetics, Incorporated (CYTK) is the lower-risk stock at 0.

80β versus Arcus Biosciences, Inc. 's 1. 84β — meaning RCUS is approximately 131% more volatile than CYTK relative to the S&P 500.

By revenue growth (latest reported year), Cytokinetics, Incorporated (CYTK) is pulling ahead at 376.

6% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Arcus Biosciences, Inc. grew EPS -4. 8% year-over-year, compared to -24. 3% for Cytokinetics, Incorporated. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcus Biosciences, Inc.

(RCUS) is the more profitable company, earning -142. 9% net margin versus -891. 6% for Cytokinetics, Incorporated — meaning it keeps -142. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCUS leads at -156. 3% versus -695. 4% for CYTK. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cytokinetics, Incorporated (CYTK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

80), +849. 5% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYTK: +849. 5%, RCUS: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CYTK is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.